These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 25340638)

  • 1. Driver and passenger mutations in cancer.
    Pon JR; Marra MA
    Annu Rev Pathol; 2015; 10():25-50. PubMed ID: 25340638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic drivers of tumourigenesis and cancer metastasis.
    Chatterjee A; Rodger EJ; Eccles MR
    Semin Cancer Biol; 2018 Aug; 51():149-159. PubMed ID: 28807546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenomic Consequences of Coding and Noncoding Driver Mutations.
    Yao X; Xing M; Ooi WF; Tan P; Teh BT
    Trends Cancer; 2016 Oct; 2(10):585-605. PubMed ID: 28741489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes.
    Cheng F; Zhao J; Zhao Z
    Brief Bioinform; 2016 Jul; 17(4):642-56. PubMed ID: 26307061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying driver mutations from sequencing data of heterogeneous tumors in the era of personalized genome sequencing.
    Zhang J; Liu J; Sun J; Chen C; Foltz G; Lin B
    Brief Bioinform; 2014 Mar; 15(2):244-55. PubMed ID: 23818492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
    Pécuchet N; Legras A; Laurent-Puig P; Blons H
    Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic Determinants of Cancer.
    Baylin SB; Jones PA
    Cold Spring Harb Perspect Biol; 2016 Sep; 8(9):. PubMed ID: 27194046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of driver copy number alterations in diverse cancer types and application in drug repositioning.
    Zhou W; Zhao Z; Wang R; Han Y; Wang C; Yang F; Han Y; Liang H; Qi L; Wang C; Guo Z; Gu Y
    Mol Oncol; 2017 Oct; 11(10):1459-1474. PubMed ID: 28719033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of constrained cancer driver genes based on mutation timing.
    Sakoparnig T; Fried P; Beerenwinkel N
    PLoS Comput Biol; 2015 Jan; 11(1):e1004027. PubMed ID: 25569148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Noncoding RNA Dysregulation and Epigenetic Mechanisms in Cancer.
    Suzuki H; Maruyama R; Yamamoto E; Niinuma T; Kai M
    Adv Exp Med Biol; 2016; 927():109-35. PubMed ID: 27376733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and epigenetic alterations of microRNAs and implications for human cancers and other diseases.
    Tuna M; Machado AS; Calin GA
    Genes Chromosomes Cancer; 2016 Mar; 55(3):193-214. PubMed ID: 26651018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional disorganization of the cancer genome occurs coincident with long-range genetic and epigenetic alterations.
    Taberlay PC; Achinger-Kawecka J; Lun AT; Buske FA; Sabir K; Gould CM; Zotenko E; Bert SA; Giles KA; Bauer DC; Smyth GK; Stirzaker C; O'Donoghue SI; Clark SJ
    Genome Res; 2016 Jun; 26(6):719-31. PubMed ID: 27053337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinguishing between driver and passenger mutations in individual cancer genomes by network enrichment analysis.
    Merid SK; Goranskaya D; Alexeyenko A
    BMC Bioinformatics; 2014 Sep; 15(1):308. PubMed ID: 25236784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
    Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
    J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered primary chromatin structures and their implications in cancer development.
    Ferraro A
    Cell Oncol (Dordr); 2016 Jun; 39(3):195-210. PubMed ID: 27007278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of accumulated alterations in driver and passenger genes on response to radiation therapy.
    Seo Y; Tamari K; Takahashi Y; Minami K; Isohashi F; Suzuki O; Sumida I; Ogawa K
    Br J Radiol; 2020 May; 93(1109):20190625. PubMed ID: 32031414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constructing an integrated genetic and epigenetic cellular network for whole cellular mechanism using high-throughput next-generation sequencing data.
    Chen BS; Li CW
    BMC Syst Biol; 2016 Feb; 10():18. PubMed ID: 26897165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer.
    Koschmann C; Nunez FJ; Mendez F; Brosnan-Cashman JA; Meeker AK; Lowenstein PR; Castro MG
    Cancer Res; 2017 Jan; 77(2):227-233. PubMed ID: 28062403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C
    Zhu CY; Zhou C; Chen YQ; Shen AZ; Guo ZM; Yang ZY; Ye XY; Qu S; Wei J; Liu Q
    Genomics Proteomics Bioinformatics; 2019 Jun; 17(3):311-318. PubMed ID: 31465854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using common variants to indicate cancer genes.
    Stead LF; Thygesen H; Westhead DR; Rabbitts P
    Int J Cancer; 2015 Jan; 136(1):241-5. PubMed ID: 24798945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.